UCLA REST Study (REsearch on Sleep Techniques)

Sponsor
University of California, Los Angeles (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05576090
Collaborator
(none)
240
1
2
58.8
4.1

Study Details

Study Description

Brief Summary

Sleep disturbance has a range of negative effects on psychosocial and biological processes important for academic and social success as well as mental and physical health among adolescents and young adults. Limited, inconsistent, and poor quality sleep lead to anxiety, depressive feelings, loneliness, and fatigue over time. These symptoms, in turn, interfere with the ability to get a good night's rest. Sleep disruption can also upregulate inflammatory processes during the years of adolescence and young adulthood in ways that can create risk for the development of chronic health conditions (e.g., diabetes, depression, cardiovascular disease) in later adulthood. Sleep, however, is also a modifiable health behavior, leading many institutions to embark upon efforts to improve the sleep of their students. The challenge is to identify programs and interventions that can simultaneously improve sleep, be delivered at scale, and be easily completed by students. UCLA has developed and validated a group-based mindfulness intervention, Mindful Awareness Practices (MAPs), that has demonstrated beneficial effects on sleep in adults and may offer a promising, scalable approach for reducing sleep disturbance and improving associated psychological and biological outcomes in college students. However, this approach requires validation in this population relative to sleep education programs, which increasingly dominate the college landscape. To address this important public health problem, the investigators propose to conduct a single site, two-arm, parallel group randomized controlled trial to test the efficacy of the validated, group-based, six-week MAPs intervention vs. sleep education, an active time and attention matched control condition, for first year undergraduate students who report poor sleep at this critical transition year. The investigators are aiming to enroll approximately 240 participants. Participants will complete questionnaires, provide blood samples for immune analysis and will be provided with wrist actigraphs to wear for 7 days, in order to collect objective measurements of sleep at pre- and post-intervention visits, and at a 3-month follow-up visit. Additional follow-up assessments will take place at 6-month, and 12-month post-intervention to evaluate persistence of effects.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness Meditation
  • Behavioral: Sleep Education
N/A

Detailed Description

Sleep disruption during college presents a significant public health concern, with studies documenting clinically-significant sleep disruption in 40-60% of college students. Poor sleep contributes to rising anxiety, depression, and loneliness as well as declining positive affect, motivation, and sense of purpose faced by many students as they attempt to navigate a successful path through college. Disrupted sleep also negatively impacts physical health, in part through up-regulating inflammatory processes that have acute and more chronic effects on a variety of health-related outcomes.

Overview: This single-site, two-arm, parallel group randomized controlled trial will evaluate the efficacy of a mindfulness-based intervention for sleep disturbance (Mindful Awareness Practices for Sleep (MAPs)) relative to an active sleep education control condition for first-year undergraduate students with sleep disturbance. Both interventions will be delivered in a group format once per week for six weeks, in the students' residential halls, and led by experienced instructors following manualized protocols. Groups will be conducted in the evenings at standardized times (weeks 3-8) during the 10-week quarter to avoid conflict with final exams. Assessments will be conducted pre- and post-intervention and at 3, 6, and 12-month post-intervention follow-ups to evaluate persistence of effects. All assessments will be conducted during the academic year.

Participants: Study participants will be first year undergraduate students at UCLA who endorse sleep disturbance as determined by a score of 8 or higher on the Insomnia Severity Index (ISI). They will be recruited in cohorts of 40 and randomized 1:1 to one of the two study arms (20 students per group, the optimal group size for the MAPs intervention). Participants will complete questionnaires and blood collection at in-person assessments conducted before and after the six-week intervention and at a 3-month post-intervention follow-up. Longer-term effects on self-reported outcomes will be assessed at 6- and 12-months post-intervention. Of note, the three follow-up assessments were scheduled to avoid the summer months given the focus on improving sleep in the college context.

Eligibility Screening: Potential participants will be directed to contact the study coordinator via email, phone, or a secure online signup form. The coordinator will then contact potential participants by phone to confirm eligibility criteria. The ISI will be administered to screen for current insomnia. Those who score an "8" or above, indicating at least sub-threshold levels of sleep disturbance, will be considered eligible for study participation. The 4-item Patient Health Questionnaire (PHQ4) survey will be used to screen for a diagnosis of a current mood or anxiety disorder. The 4-item PHQ-4 screening measure provides a good measure of "caseness" for both anxiety and depression that has been validated in college samples. If a potential subject scores a "3" on either subscale, the study coordinator will administer the 8-item Patient Health Questionnaire (PHQ8) for depression or the 7-item Generalized Anxiety Disorder (GAD-7) for anxiety, to determine the severity. If the potential participant scores "15" or more on either scale, they will be referred to the UCLA Counseling and Psychological Services (CAPS). Screening will continue until there are 45-50 participants who are eligible, interested, and available to participate in the next cohort. With expected attrition of 5-10 students between screening and enrollment/baseline assessment, this will allow the investigators to obtain a desired group size of 20 per group.

Enrollment and Baseline Assessment (T1). All students who are determined to be eligible will be scheduled for an in-person, baseline assessment (T1) at the UCLA Health Psychology Laboratory (HPL). The Institutional Review Board (IRB) approved consent form will be reviewed and signed. Height and weight will be collected. A pre-intervention online survey will also be completed during this initial in-person visit. The survey will consist of the following scales: Background demographic characteristics, health behaviors, Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Anxiety and Preoccupation with Sleep (APSQ), Center for Epidemiological Studies-Depression (CES-D), Generalized Anxiety Disorder-7 (GAD-7), Multi-dimensional Fatigue Symptom Inventory Short Form (MFSI-SF), Perceived Stress Scale (PSS), UCLA Loneliness Scale, Positive affect (PANAS-X), Mental Health Continuum-short form (MHC-SF), Mindfulness scale (FFMQ), Self-kindness scale, and the Rumination and reflection questionnaire.

Participants will provide blood samples for immune evaluation. Due to changes in research procedures due to COVID-19, the investigators would like to change the usual method for blood collection. Prior to COVID-19, blood was drawn by venipuncture by a licensed phlebotomist. However, in order to mitigate risk and abide to social distancing guidelines. the investigators now plan to collect blood by utilizing the Tasso OnDemand device, which allows self-collection of a single capillary blood sample and does not require venipuncture. The Tasso device sticks to the skin with a light adhesive. When the button is pressed, a vacuum forms and a lancet pricks the surface of the skin. The vacuum draws blood out of the capillaries and into a sample pod attached to the bottom of the device. The participant would watch a demonstration video during their baseline assessment visit, and then use the device to collect a blood sample. Approximately 1/8th of a teaspoon of blood will be drawn at each in-person assessment.

Participants will be provided with a wrist actigraph (Micro Motionlogger Sleep Watch, Ambulatory Monitoring, Inc.; Ardsley, NY) to wear on their non-dominant hand for seven consecutive 24-hour periods. They will be instructed to keep it on at all times, removing only for bathing. Participants will be instructed to press the event marker on the actigraph to indicate when they: 1) turn off the lights to go to sleep at night, 2) get out of bed in the middle of the night, such as to use the bathroom, 3) get out of bed in the morning, and 4) begin and end daytime naps. The software package Action 4 (Ambulatory Monitoring, Inc.; Ardsley, NY) will be used to code and score the actigraphy data, and established algorithms will be used to provide estimates of parameters such as sleep duration, sleep onset latency, efficiency, daily variability, and wakenings after sleep onset.

Assessments will be scheduled in the morning to control for diurnal variations in immune parameters. Baseline visits will be conducted in the 2-week period before intervention onset.

Randomization: Following baseline assessment, participants will be randomized to one of the two study conditions. The randomization sequence will be generated using the PLAN procedure in SAS 9.4, with 1:1 allocation using permuted blocks with random block sizes of 2, 4, and 6, under the direction of project biostatistician, Dr. Crespi. The randomization table will be uploaded into REDCap, and the study coordinator will use the REDCAP "Randomize" procedure to determine the participant's assigned condition. The coordinator will inform the participants of their assigned condition and provide information on the intervention.

Interventions: Both interventions will be held in private rooms in the residential part of the UCLA campus, close to student living quarters. Group sessions will be conducted in the evenings and scheduled to occur mid-way through the quarter (weeks 3-8 of the 10-week quarter) to minimize conflict with classes and exam periods.

Mindful Awareness Practices for Sleep (MAPs): Participants assigned to this condition will be asked to attend two-hour group sessions once a week for six weeks. The MAPs intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA and adapted to specifically address sleep disturbance. The MAPs program is similar to other mindfulness-based interventions in its general focus on cultivating mindfulness, but takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life (as compared to the focus on stress and stress reduction in mindfulness-based stress reduction). Key components of the intervention include development of bodily awareness, managing pain, working with difficult thoughts and feelings, cultivating positive emotions and loving kindness, and relational mindfulness practices. The MAPs curriculum will be implemented by trained instructors who will receive specialized training in delivery of the study-specific protocol and will be overseen by Dr. Marvin Belzer, Associate Director of the MARC and master instructor for this trial.

Sleep Education (SE): Participants assigned to this condition will be asked to attend a two-hour group session once a week for 6 weeks. This program is based on the sleep education program used by Dr. Michael Irwin and colleagues, and matches the MAPs condition for time, attention, group interaction, and expectancy of benefit. The SE intervention provides education and behavioral content based on the National Institutes of Health and National Sleep Foundation tips for better sleep (e.g., changing poor sleep habits and establishing a bedtime routine).The standardized program will be implemented by trained health educators who will receive specialized training in delivery of the study-specific protocol with oversight by Co-I Dr. Michael Irwin.

Immediate Post-Intervention Assessment (T2): This in-person visit will be scheduled to occur within 2 weeks after the conclusion of the study interventions at the UCLA HPL and will include completion of study questionnaires, collection of blood samples, and 7 days of actigraphy.

3-, 6-, and 12-month Follow-up Assessments (T3,T4,T5). All participants will be asked to complete follow-up assessments at 3 months (T3), 6 months (T4), and 12 months (T5) post-intervention. The T3 assessment will be conducted at the UCLA HPL and will include completion of questionnaires, blood collection, and 7 days of actigraphy. T4 and T5 assessments will involve completion of online study questionnaires only (no blood draw or actigraphy). This assessment schedule will allow the investigators to capture short- and long-term effects.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
After completing the pre-intervention T1 assessment (consisting of completing an online survey, a blood draw and wearing an actigraphy watch for 7 days), study subjects will be randomized to one of the two study conditions. Study subjects will be informed of their assigned condition and will be provided with specific details to the intervention class when they come back to return the actigraphy watch.After completing the pre-intervention T1 assessment (consisting of completing an online survey, a blood draw and wearing an actigraphy watch for 7 days), study subjects will be randomized to one of the two study conditions. Study subjects will be informed of their assigned condition and will be provided with specific details to the intervention class when they come back to return the actigraphy watch.
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Mindful Awareness Practices vs. Sleep Education: Improving Sleep Quality During the Transition to College
Anticipated Study Start Date :
Feb 6, 2023
Anticipated Primary Completion Date :
Dec 31, 2027
Anticipated Study Completion Date :
Dec 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness Meditation

Half of the subjects will be randomly assigned to participate in the Mindfulness Meditation intervention. This class will meet once a week, for two hours, over the course of six weeks.

Behavioral: Mindfulness Meditation
The mindful awareness practices (MAPS) for Sleep intervention is based on an institutional program developed by the Mindful Awareness Research Center (MARC) at UCLA. This intervention includes educational and behavioral content related to sleep, including the importance of regularity of sleep schedules, minimizing noise and light, and reducing caffeine use later in the day. Each session provides structured training and exercises in mindfulness, including formal meditation practices and strategies for the daily informal use of mindfulness, as well as opportunity for group discussion and sharing. Home practice is a key component of MAPs and is particularly important for addressing sleep disturbance. Participants will be instructed to practice mindfulness techniques on a daily basis, beginning with five minutes and increasing to 20 minutes, with practice prior to bedtime, and to practice at night if they awake and cannot return to sleep.
Other Names:
  • MAPS for Sleep Intervention
  • Active Comparator: Sleep Education

    Half of the subjects will be randomly assigned to participate in the Sleep Education intervention. This class will meet once a week, for two hours, over the course of six weeks.

    Behavioral: Sleep Education
    The Sleep Education intervention provides education and behavioral content based on the National Institutes of Health and National Sleep Foundation tips for better sleep (e.g., changing poor sleep habits and establishing a bedtime routine). Each session provides didactic instruction, review of behavioral techniques, and opportunity for group discussion and sharing, comparable to that offered in the MAPs classes. Homework includes practicing sleep hygiene and weekly reading. Key components of the intervention include information about sleep biology, characteristics of healthy and unhealthy sleep, sleep problems, stress biology and stress reduction, self-monitoring of sleep behavior, relaxation methods for improving sleep, and weekly behavioral sleep hygiene strategies.

    Outcome Measures

    Primary Outcome Measures

    1. Sleep disruption (sleep latency, sleep duration, sleep efficiency, sleep disturbance and daytime dysfunction) [Baseline, at 8 weeks and at 20 weeks]

      Changes in sleep disruption Sleep disruption will be measured via the Pittsburgh Sleep Quality Index. 19 self-rated items are combined to form seven "component" scores, (sleep latency, sleep duration, sleep efficiency, sleep disturbance, daytime dysfunction, with subjective sleep quality rated by participant, and use of sleep medications included in scale) each of which ranges from 0-3 points ("0 indicates no difficulty, while "3" indicates severe difficulty). The seven component scores are combined into one "global" score, ranging from 0-21 points. Higher scores indicate greater sleep disruption.

    Secondary Outcome Measures

    1. Insomnia severity [Baseline, at 8 weeks and at 20 weeks]

      Change in the severity of insomnia problems The severity of insomnia problems will be measured via the Insomnia Severity Index (ISI). The ISI consists of 7 items which are summed for a total score (range: 0-28) with higher scores indicating greater insomnia severity. Scores of 8-14 indicate subthreshold insomnia, while scores of 15-28 indicate clinical insomnia.

    2. Worries about Sleep [Baseline, at 8 weeks and at 20 weeks]

      Changes in anxiety and preoccupation about sleep difficulties Worries about sleep difficulties will be measured via the Anxiety and Preoccupation with Sleep Questionnaire (APSQ). The APSQ has 10 items that can be summed for a total score (range: 10-100). There are also 2 subscales: 6-items determine worries about the consequences of poor sleep and 4-items assess worries about the uncontrollability with sleep, each of which can be summed for a subscale total score. Higher scores indicate greater anxiety and preoccupation about sleep difficulties.

    3. Mindfulness [Baseline, at 8 weeks and at 20 weeks]

      Change in Mindfulness Mindfulness will be measured via the 15-item Five Facet Mindfulness Questionnaire (FFMQ-15). The FFMQ-15 has both direct and reverse scoring items and is comprised of 5 facets: observing, describing, acting with awareness, non-judgment and non-reactivity, along with an overall mindfulness score. The total FFMQ can be divided by 15 to get an average item score. Scores represent a spectrum of mindfulness.

    4. Depression [Baseline, at 8 weeks and at 20 weeks]

      Change in depressive symptoms Depressive symptoms will be measured via the 20-item Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a measure of symptom severity, with higher scores (range: 0-60) indicating greater depressive symptoms

    5. Psychological well-being [Baseline, at 8 weeks and at 20 weeks]

      Change in psychological well-being Well-being will be measured via the 14-item Mental Health Continuum-Short Form (MHC-SF). The MHC-SF is comprised of three empirically derived subscales: the 3-item Emotional Well-Being Subscale, the 6-item Psychological Well-Being Subscale, and the 5-item Social Well-Being Subscale. Higher scores on each subscale, and the total score overall (range: 0-56), indicate greater well-being.

    6. Anxiety [Baseline, at 8 weeks and at 20 weeks]

      Change in anxiety Symptoms of anxiety will be measured via the 7-item Generalized Anxiety Disorder- 7 (GAD-7). Higher scores on the GAD-7 (range: 0-21) indicate greater severity of symptoms

    7. Positive Affect [Baseline, at 8 weeks and at 20 weeks]

      Change in positive affect Reports of positive affect will be assessed via the 10-item positive affect subscale, the 3-item serenity subscale and the 8-item joviality subscale from the Positive and Negative Affect Schedule (PANAS-X). Greater scores indicate higher feelings of positive affect (range: 21-105).

    8. Perceived Stress [Baseline, at 8 weeks and at 20 weeks]

      Change in perceived stress Perceived stress will be measured via the 10-item Perceived Stress Scale (range: 0-40). Higher scores indicate greater perceived stress levels.

    9. Fatigue [Baseline, at 8 weeks and at 20 weeks]

      Change in fatigue Fatigue will be measured via the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) general fatigue subscale. This subscale consists of 6 items which are scored for a total sum (range: 0-24). Higher scores indicate greater general fatigue.

    10. Loneliness [Baseline, at 8 weeks and at 20 weeks]

      Change in loneliness Loneliness will be measured via the 3-item UCLA Loneliness Scale (range: 3-9). Higher scores indicate greater loneliness

    11. Self-kindness [Baseline, at 8 weeks and at 20 weeks]

      Change in self-kindness Self-kindness will be measured via the 5-item Self-kindness subscale from the Self-Compassion Scale. A self-kindness score is computed by calculating the mean of the 5-items. Higher scores indicate greater self-kindness.

    12. Rumination [Baseline, at 8 weeks and at 20 weeks]

      Change in Rumination Rumination will be measured via the 6-item rumination subscale from the Rumination and Reflection questionnaire. Some items require reverse scoring. Rumination reflects a tendency to focus on negative self-perceptions.

    13. Inflammation [Baseline, at 8 weeks and at 20 weeks]

      Change in Inflammation Pro- inflammatory gene expression will be measured through a set of 19 pre-specified pro-inflammatory gene transcripts that have previously been shown to be upregulated in the context of chronic stress and downregulated by the mindfulness meditation intervention. The inflammatory composite includes the following genes: IL1A, IL1B, IL6, IL8, TNF, PTGS1, PTGS2, FOS, FOSB, FOSL1, FOSL2, JUN, JUNB, JUND, NFKB1, NFKB2, REL, RELA, and RELB). Meso Scale Discovery multiplex immunoassays will be used to assess 5 key pro- and anti-inflammatory cytokines (IL-6, IL-8, IL-10, TNF-α, IFN-γ), and R&D Systems ELISA will assess the chronic inflammatory marker CRP.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 20 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • First year undergraduate student at UCLA

    • Ages 18-20 years old

    • Must live in the residential halls on UCLA campus

    • Must have a score of 8 or above on the Insomnia Severity Index (ISI), indicating at least sub-threshold levels of sleep disturbance.

    Exclusion Criteria

    • Current diagnosis of mood or anxiety disorder as determined by the PHQ-8 or by the GAD-7 if score "15" or more on either measure

    • Presence of medical conditions or use of medications that may influence inflammation (e.g., autoimmune disorder)

    • Regular tobacco use

    • Actively practicing mindfulness meditation or receiving formal sleep education

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California, Los Angeles Los Angeles California United States 90095

    Sponsors and Collaborators

    • University of California, Los Angeles

    Investigators

    • Principal Investigator: Julienne E Bower, Ph.D., University of California, Los Angeles
    • Principal Investigator: Andrew Fuligni, Ph.D., University of California, Los Angeles

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Julienne Bower, PhD, Associate Professor, University of California, Los Angeles
    ClinicalTrials.gov Identifier:
    NCT05576090
    Other Study ID Numbers:
    • 22-000229
    First Posted:
    Oct 12, 2022
    Last Update Posted:
    Jan 23, 2023
    Last Verified:
    Jan 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Julienne Bower, PhD, Associate Professor, University of California, Los Angeles
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 23, 2023